Efficacy and safety of anti-vascular endothelial growth factor agents on corneal neovascularization: A meta-analysis

Table 3 Summary of all results

Trial/Study	Target	Comparison	Brief conclusion	Overall RoB
Efficacy of reducing CoNV
Hamdan et al[18]	All pathologies	SC B vs PDT vs combined	B = PDT = combined	SC
Ozgurhan et al[21]	Pterygium	Topi B vs placebo	B > placebo	SC
Bhatti et al[15]	Transplant	Topi B vs placebo	B > placebo	H
Dohlman et al[16]	Transplant	SC + Topi B vs placebo	B > placebo	L
Li et al[20]	Transplant	Placebo vs SC B vs SC B + TA vs SC TA	B = combined > TA = placebo	H
Petsoglou et al[22]	All pathologies	SC B vs placebo	B > placebo	L
Kim et al[19]	All pathologies	SC B vs SC R	B > R	SC
You et al[23]	All pathologies	SC B 1.25 mg vs SC B 2.5 mg vs SC B 5 mg	1.25 mg < 2.5 mg = 5 mg	SC
Hurmeric et al[25]	Pterygium	SC R ×1 vs SC R ×3	R ×1 = R ×3 (Statistical analysis not conducted)	S
Pooled results of three trials[16,20,22] showed B > placebo on reducing CoNV
Efficacy of improving BCVA/VA
Li et al[20]	Transplant	Placebo vs SC B vs SC B + TA vs SC TA	B > pre-treatment (No statistical detail)	H
Bhatti et al[15]	Transplant	Topi B vs placebo	B > placebo	H
Dohlman et al[16]	Transplant	SC + Topi B vs placebo	B = placebo	L
Huang et al[24]	Transplant	SC B vs placebo	B > placebo	M
Petsoglou et al[22]	All pathologies	SC B vs placebo	B = placebo	L
Kim et al[19]	All pathologies	SC B vs SC R	B = R = pre-treatment	SC
You et al[23]	All pathologies	SC B 1.25 mg vs 2.5 mg vs 5 mg	1.25 mg = 2.5 mg = 5 mg = pre-treatment	SC
Pooled results of two trials[22,24] showed B > placebo on improving VA
Efficacy of reducing graft rejection/failure
Li et al[20]	Transplant	Placebo vs SC B vs SC B + TA vs SC TA	B, C > pre-treatment (No statistical detail)	H
Dohlman et al[16]	Transplant	SC + Topi B vs placebo	B = placebo	L
Fasciani et al[17]	Transplant	SC B vs placebo	B > placebo	H
Huang et al[24]	Transplant	SC B vs placebo	B > placebo	M
Trufanov et al[26]	Transplant	SC A vs SC A + laser vs placebo	A = A + laser > placebo (statistical analysis not conducted)	S
Pooled results of four trials[16,17,24,26] showed B > placebo on reducing rejection/failure risks

A: Aflibercept; B: Bevacizumab; BCVA: Best-corrected visual acuity; CoNV: Corneal neovascularization; PDT: Photodynamic therapy; R: Ranibizumab; RoB: Risk of bias (RoB judgment: H: High; S: Serious; SC: Some concerns; M: Moderate; L: Low); SC: Subconjunctival; TA: Triamcinolone acetonide; Topi: Topical; VA: Visual acuity.